文献速递心脑血管急症

0/2小时高敏心肌肌钙蛋白T诊断方案在美国多中心队列中的表现

Performance of the 0/2-hour high-sensitivity cardiac troponin T diagnostic protocol in a multisite United States cohort.
PubMed 文献 · Acad Emerg Med · 2024-01-08
一句话结论在美国8家急诊科,hs-cTnT 0/2小时算法排除61.4%患者,但排除区30天CDMI的NPV仅98.1%,作者认为许多急诊医生可能不认为其安全。

本研究为STOP-CP队列研究的预计划亚组分析,纳入2017年1月至2018年9月美国8家急诊科前瞻性入组的1307例急診胸痛患者,使用hs-cTnT 0/2小时算法单独或联合HEAR评分进行分层。30天CDMI发生率为12.9%(168/1307)。单独算法排除61.4%(802/1307)患者,排除区30天CDMI发生率为1.9%(15/802),敏感度91.1%(95%CI 85.7%-94.9%),NPV 98.1%(95%CI 96.9%-98.9%);算法纳入12.4%(162/1307)患者,其中61.7%(100/162)发生30天CDMI,特异度94.6%(95%CI 93.1%-95.8%),PPV 61.7%(95%CI 53.8%-69.2%)。联合HEAR评分排除30.7%(401/1307)患者,敏感度98.2%(95%CI 94.9%-99.6%),NPV 99.3%(95%CI 97.8%-99.8%)。作者认为,单独0/2小时算法NPV<99%,许多急诊医生可能不认为对美国急诊患者安全;联合低危HEAR评分NPV>99%,但效率降低。

要点

  • 在美国8家急诊科1307例急性胸痛患者中,hs-cTnT 0/2小时算法排除61.4%(802/1307),但排除区30天CDMI发生率为1.9%(15/802),NPV 98.1%(95%CI 96.9%-98.9%),敏感度91.1%(95%CI 85.7%-94.9%)。
  • 单独0/2小时算法纳入12.4%(162/1307)患者,其中61.7%(100/162)发生30天CDMI,特异度94.6%(95%CI 93.1%-95.8%),PPV 61.7%(95%CI 53.8%-69.2%)。
  • 联合HEAR评分后排除30.7%(401/1307)患者,敏感度98.2%(95%CI 94.9%-99.6%),NPV 99.3%(95%CI 97.8%-99.8%),但排除效率较单独算法降低。
  • 作者认为,单独0/2小时算法NPV<99%,许多急诊医生可能不认为其对美国急诊患者安全;联合低危HEAR评分NPV>99%,但效率降低。

适用人群与场景

  • 美国8家急诊科前瞻性入组的急診胸痛患者,具有0小时和2小时hs-cTnT检测结果,年龄57.5±12.7岁,53.6%(700/1307)为男性,58.6%(762/1307)为白人。

诊断标准与关键阈值

  • 使用hs-cTnT 0/2小时算法将患者分为排除区、观察区和纳入区,具体阈值未在原文给出。
  • 联合使用病史、心电图、年龄和危险因素(HEAR)评分进行风险分层。

研究设计与关键结果

  • 研究类型:STOP-CP队列研究的预计划亚组分析,美国8家急诊科前瞻性入组,2017年1月至2018年9月,样本量1307例。
  • 30天CDMI总发生率为12.9%(168/1307)。
  • 单独hs-cTnT 0/2小时算法:排除61.4%(802/1307)患者,排除区30天CDMI发生率1.9%(15/802),敏感度91.1%(95%CI 85.7%-94.9%),NPV 98.1%(95%CI 96.9%-98.9%);纳入12.4%(162/1307)患者,其中61.7%(100/162)发生30天CDMI,特异度94.6%(95%CI 93.1%-95.8%),PPV 61.7%(95%CI 53.8%-69.2%)。
  • 联合HEAR评分:排除30.7%(401/1307)患者,敏感度98.2%(95%CI 94.9%-99.6%),NPV 99.3%(95%CI 97.8%-99.8%)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究的预计划亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,单独hs-cTnT 0/2小时算法NPV<99%,许多急诊医生可能不认为其对美国急诊患者安全。
  • 作者认为,联合低危HEAR评分后NPV>99%,但以降低排除效率为代价。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The diagnostic performance of the high-sensitivity troponin T (hs-cTnT) 0/2-h algorithm is unclear among U.S. emergency department (ED) patients with acute chest pain.

METHODS: A preplanned subgroup analysis of the STOP-CP cohort study was conducted. Participants with 0- and 2-h hs-cTnT measures prospectively enrolled at eight U.S. EDs from January 2017 to September 2018 were stratified into rule-out, observation, and rule-in zones using the hs-cTnT 0/2-h algorithm alone and combined with the history, electrocardiogram, age, and risk factor (HEAR) score. The primary outcome was adjudicated 30-day cardiac death or myocardial infarction (CDMI). The sensitivity and negative predictive value (NPV) of the 0/2-h rule-out zone and specificity and positive predictive value (PPV) of the rule-in zone for 30-day CDMI were calculated.

RESULTS: Of the 1307 patients accrued, 53.6% (700/1307) were male and 58.6% (762/1307) were White, with a mean ± SD age of 57.5 ± 12.7 years. At 30 days, CDMI occurred in 12.9% (168/1307) of participants. The 0/2-h algorithm ruled out 61.4% (802/1307) of patients. Among rule-out patients, 1.9% (15/802) experienced 30-day CDMI, resulting in a sensitivity of 91.1% (95% confidence interval [CI] 85.7%-94.9%) and NPV of 98.1% (95% CI 96.9%-98.9%). The 0/2-h algorithm ruled in 12.4% (162/1307) patients of whom 61.7% (100/162) experienced 30-day CDMI. The rule-in zone specificity was 94.6% (95% CI 93.1%-95.8%) and PPV was 61.7% (95% CI 53.8%-69.2%) for 30-day CDMI. The 0/2-h algorithm combined with HEAR score ruled out 30.7% (401/1307) of patients with a sensitivity and NPV for 30-day CDMI of 98.2% (95% CI 94.9%-99.6%) and 99.3% (95% CI 97.8%-99.8%), respectively.

CONCLUSIONS: The hs-cTnT 0/2-h algorithm ruled out most patients. With NPV of <99% for 30-day CDMI, the hs-cTnT 0/2-h algorithm, many emergency physicians may not consider it safe to use for U.S. ED patients. When combined with a low-risk HEAR score, NPV was >99% for 30-day CDMI at the cost of reduced efficacy.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Supples MW, Snavely AC, Ashburn NP, et al. Performance of the 0/2-hour high-sensitivity cardiac troponin T diagnostic protocol in a multisite United States cohort. Acad Emerg Med. 2024. PMID: 37925594. doi:10.1111/acem.14827

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。